NCT06394986

Cardio-fistular Recirculation in Patients With Chronic Heart Failure and Preserved Left Ventricle Ejection Fraction

Name: Clinical Trial NCT06394986
Creator: Moscow Regional Research and Clinical Institute (MONIKI)
Keywords: Chronic Kidney Disease 5D,Heart Failure,Heart Failure NYHA Class I,Heart Failure NYHA Class II, Hemodialysis session, procedure, clinical trial, Russian Federation

Moscow Regional Research and Clinical Institute (MONIKI)·ClinicalTrials.gov·procedureCompleted

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Chronic Kidney Disease 5D,Heart Failure,Heart Failure NYHA Class I,Heart Failure NYHA Class II
Drug/Device/Intervention: Hemodialysis session
Study type: Observational
Intervention type: procedure

Sponsor & location

Primary sponsor: Moscow Regional Research and Clinical Institute (MONIKI)
Location: Moscow, Russian Federation

Timeline & enrollment

Phase: N/A
Start date: Jun 18, 2018
End date: Feb 18, 2019
Enrollment: 20 participants

Primary outcome

Change in cardio-fistular recirculation

Summary

This is a single-arm cohort study aimed to evaluate change of arteriovenous fistula volume blood flow / cardiac output ratio in patients with chronic heart failure (NYHA I-II classes) and with preserved ejection fraction as a result of a hemodialysis session after a long interdialysis interval.

ICD-10 classifications

Chronic kidney disease, stage 5Chronic kidney disease, unspecifiedHypertensive heart and renal disease with (congestive) heart failureHypertensive heart and renal disease with both (congestive) heart failure and renal failureChronic kidney disease

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT06394986
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT06394986 through Pure Global AI's free database. This phase not specified trial is sponsored by Moscow Regional Research and Clinical Institute (MONIKI) and is currently Completed. The study focuses on Chronic Kidney Disease 5D,Heart Failure,Heart Failure NYHA Class I,Heart Failure NYHA Class II. Target enrollment is 20 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.